PROTECT Series of Clinical Studies Provides Mounting Evidence for Impella Support in High-risk PCI

Looking at the data from the PROTECT Series—PROTECT I1, PROTECT II RCT2, and PROTECT III—William O’...

National Cardiogenic Shock Initiative Update

Dr. Bill O’Neill Discusses Ongoing Progress in NCSI Bill O’Neill, MD presents some of the overall...

Publication Review: Amin Analysis on Impella and IABP

Review of Trends, Variation and Outcomes in Impella® Use Dr. Seth Bilazarian, Abiomed’s Chief Medical Offi...

Cost-effectiveness and Impella

Dr. George Vetrovec Discusses Impella Cost Effectiveness Dr. George Vetrovec, professor of medicine, emeritus, at Virg...

Contemporary Landscape of PCI and RESTORE EF

TCT 2019 Presentation from SCAI President Dr. Ehtisham Mahmud At TCT 2019, Dr. Ehtisham Mahmud gave a...

NCSI Findings Regarding Right Ventricular Dysfunction

About 40% of AMICS Patients Develop Right Ventricular Dysfunction Dr. Babar Basir, an interventionalist at Henry Ford...

Does Impella Affect Predicted AKI Risk?

Study Shows a 78% Risk Decrease in Overall Incidence of Post-procedural AKI Dr. Michael Flaherty pres...

Impella Support and Acute Kidney Injury During High-Risk PCI

Results from the cVAD Study™ on Renal Protection Dr. Michael Flaherty presents data on...

New PROTECT III Data Demonstrates Impella® Reduces MACCE at Primary Endpoint

Jeffrey J. Popma, MD, presents new data from ongoing FDA post-approval study for PROTECT II randomized control trial. &n...

Summary of AKI Data with Impella Unloading

Study shows lower than predicted incidence of post-procedural AKI in Protected PCI patients Dr. Seth Bilazarian, chief...

Roma Verona Impella ProPCI Study Summary with Dr. Burzotta and Dr. Trani

Complete Revascularization Associated with Significant Improvement in LVEF and Long-term Survival In this video, Dr. A...

New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients

Dr. Shon Chakrabarti shares information on a recent publication from the Journal of Interventional Cardiology by Dr. Francesco...

New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery

New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients...

Dr. Seth Bilazarian on the recent Circulation paper by Dr. Schrage/Dr. Ibrahim

Dr. Seth Bilazarian discusses a recent paper published in Circulation by Drs. Benedikt Schrage, Karim Ibrahim, et. al....

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...

Use of Impella® Device to Assess Left Ventricular Function: A Proof-of-Concept Study

Left ventricular end-diastolic pressure (LVEDP) refers to the pressure in the LV at the end of diastolic filling and immediatel...

Roundtable Discusses Protected PCI for High-Risk Patients

In the video below, Dr. John Lasala from Washington University, St. Louis, Missouri, hosts a roundtable discussion on Protected...